Galectin Therapeutics Inc.

Go to Galectin Therapeutics Inc. Website

$3.65

0.06 (1.67%)
Live
Previous Close

$3.69

Day Range

$3.5 - $3.71

Previous Day Range

$3.465 - $3.7776

Market Cap

$227.2 million USD

Day Vol.

176224

Previous Day Vol.

239668

Currency

USD

Primary Exchange

Nasdaq

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (G...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

Galectin Therapeutics is hosting a virtual event to discuss its drug belapectin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The event will feature key opinion leaders and highlight results from the company's NAVIGATE Phase 3 clinical trial.

Related tickers: GALT.

Read Full Article

Galectin Therapeutics announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented at the 2025 MASH-TAG Conference. The company's executive leadership will also host one-on-one meetings during the JP Morgan Healthcare Conference to discuss the NAVIGATE topline results and the next steps for the belapectin program.

Related tickers: GALT.

Read Full Article
Trending Tickers

Please sign in to view